Victoria Socha

DocwireNews

Therapy with renin-angiotensin-aldosterone system inhibitors (RAASi) confers renoprotective benefits on patients with chronic kidney disease, but increases the risk for hyperkalemia. Guideline recommendations call for maintenance of RAASi therapy using novel antihyperkalemia treatment. However, according to Anhay Rastogi and colleagues, RAASi therapy is often limited or withdrawn in patients with hyperkalemia.The researchers conducted an observational study to examine the risk of progression to end-stage kidney disease (ESKD) associated with hyperkalemia-related RAASi therapy reduction in patients with CKD. Results were reported during a poster session at the American Society of Nephrology Kidney Week 2023 in a poster titled Association Between Reduced RAASi Therapy and Progression to ESKD in Hyperkalemia CKD Patients.The study utilized data from hospital records and claims from the United States (Optum&rsquo;s deidentified Market Clarity Data) and Japan (Medical Data Vision). Eligible patients were individuals with CKD stage 3/4 and baseline RAASi use with an International Classification of Diseases, Tenth Revision code for hyperkalemia during July 2019 to September 2021 for the US cohort and May 2020 to September 2021 for the Japanese cohort.Based on RAASi prescriptions 3 months prior to the index hyperkalemic episode versus after the episode, patients were categorized as down-titrated, discontinued, or maintained treatment. ESKD was defined as diagnosis of CKD stage 5 or ESKD. The study compared the risk of progression to ESKD within 6 months in patients who down-titrated or discontinued RAASi therapy with those who maintained RAASi therapy.The cohorts included 11,873 (US) and 1427 (Japan) patients. Mean age was 71 years in the United States and 76 years in Japan. The US cohort was 52% male and the Japanese cohort was 66% male. In the US cohort, 7506 patients filled a prescription for an RAASi within 3 months prior to the index event and had &ge;3 months of follow-up. Of those, 33% discontinued and 6% down-titrated. Among the corresponding patients in Japan (n=1179), 27% discontinued and 5% down-titrated.The risk of progression to ESKD was 70% to 74% higher in all patients who discontinued, and 60% higher in patients in the US cohort who down-titrated versus those who maintained RAASi therapy.&ldquo;Hyperkalemia-promoted RAASi therapy reduction is associated with increased risk of progression to ESKD, indicating a need for improved guideline adherence in managing hyperkalemia to maintain RAASi therapy,&rdquo; the researchers said.Source: Rastogi A, Pollack C, Les&eacute;n E, et al. Association between RAASi therapy and progression to ESKD in hyperkalemic CKD patients. Th-PO1028. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2023; November 2, 2023; Philadelphia, Pennsylvania. Funding was provided by AstraZeneca plc.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Reductions in RAASi Therapy and Risk of ESKD in Patients With Hyperkalemia

Hyperkalemia

Therapy with renin-angiotensin-aldosterone system inhibitors confers renoprotective benefits on patients with chronic kidney disease, but increases the risk for hyperkalemia.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe